Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SBFM

SBFM - Sunshine Biopharma Inc. Stock Price, Fair Value and News

$1.31+0.03 (+2.34%)
Market Closed

86/100

SBFM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

86/100

SBFM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.84

Target 3M

$1.54

Target 6M

$1.66

SBFM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SBFM Price Action

Last 7 days

4.0%

Last 30 days

6.5%

Last 90 days

-25.1%

Trailing 12 Months

-54.2%

SBFM RSI Chart

SBFM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SBFM Valuation

Market Cap

6.4M

Price/Earnings (Trailing)

-1.07

Price/Sales (Trailing)

0.17

EV/EBITDA

0.46

Price/Free Cashflow

-0.87

SBFM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.84

Target 3M

$1.54

Target 6M

$1.66

SBFM Fundamentals

SBFM Revenue

Revenue (TTM)

37.3M

Rev. Growth (Yr)

11.64%

Rev. Growth (Qtr)

0.07%

SBFM Earnings

Earnings (TTM)

-6.0M

Earnings Growth (Yr)

26.21%

Earnings Growth (Qtr)

50.09%

SBFM Profitability

Operating Margin

33.01%

EBT Margin

-17.44%

Return on Equity

-24.76%

Return on Assets

-19.03%

Free Cashflow Yield

-115.22%

SBFM Investor Care

Shares Dilution (1Y)

145.34%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202536.2M36.3M37.3M0
202426.7M30.5M33.0M34.9M
20239.1M14.5M20.4M24.1M
2022327.5K424.9K507.3K4.3M
202154.8K87.3K130.8K212.0K
202097.2K111.2K101.7K71.4K
2019158.5K108.8K114.7K106.1K
2018115.5K149.3K183.2K217.1K
201773.2K76.0K78.8K81.6K
2016150.1K355.4K329.7K70.4K
2015265.8K146.4K152.4K164.8K
2014184.1K278.5K270.7K268.3K
20130167.5K172.9K157.0K
201237.8K48.5K92.7K101.9K
201157.1K48.9K40.7K32.5K
201000065.3K
Get all data in R, Python etc through our Historical Stock Data APIs

About Sunshine Biopharma Inc.

SBFM
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in Pointe-Claire, Canada.
 CEO
 WEBSITEhttps://sunshinebiopharma.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES46

Sunshine Biopharma Inc. Frequently Asked Questions

SBFM is the stock ticker symbol of Sunshine Biopharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Sunshine Biopharma Inc. is 6.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SBFM's fair value in chart for subscribers.

The fair value guage provides a quick view whether SBFM is over valued or under valued. Whether Sunshine Biopharma Inc. is cheap or expensive depends on the assumptions which impact Sunshine Biopharma Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SBFM.

As of Wed Jan 28 2026, SBFM's PE ratio (Price to Earnings) is -1.07 and Price to Sales (PS) ratio is 0.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SBFM PE ratio will change depending on the future growth rate expectations of investors.